Tasas y factores asociados a la remisión de la diabetes mellitus tipo 2 tras bypass gástrico en pacientes con obesidad

Romina Riquelme; Marta Inés Ferreira Gaona; Francisco Javier Cabrera López; Elizabeth Analía Valinotti Delmás

doi:10.66201/ss.v1.22

Authors

Romina Riquelme The "Instituto de Prevision Social" Author
Marta Inés Ferreira Gaona The "Instituto de Prevision Social" Author https://orcid.org/0000-0001-6876-4902
Francisco Javier Cabrera López The "Instituto de Prevision Social" Author
Elizabeth Analía Valinotti Delmás The "Instituto de Prevision Social" Author

DOI:

https://doi.org/10.66201/ss.v1.22

Keywords:

Bariatric Surgery, Obesity, Gastric Bypass, Diabetes Remission, Type 2 Diabetes Mellitus

Abstract

Introduction: Bariatric surgery, particularly Roux-en-Y gastric bypass, has demonstrated high effectiveness in achieving remission of type 2 diabetes mellitus (T2DM) in patients with obesity. However, remission rates and associated predictive factors vary among populations. The aim of this study was to determine the rates and factors associated with T2DM remission after gastric bypass in patients with obesity treated at a referral center in Paraguay.

Methodology: Observational, retrospective, cross-sectional study including adult patients with obesity and T2DM who underwent Roux-en-Y gastric bypass between 2018 and 2023. Clinical, biochemical, and anthropometric variables were analyzed before and after surgery. Diabetes remission was defined according to the American Diabetes Association criteria.

Results: Most patients achieved partial or complete remission of T2DM after surgery. Factors significantly associated with remission included shorter duration of diabetes, lower preoperative HbA1c levels, absence of insulin therapy, and greater postoperative weight loss.

Conclusions: Roux-en-Y gastric bypass was associated with high rates of T2DM remission in patients with obesity. Clinical and metabolic characteristics before surgery may help predict the likelihood of remission and optimize patient selection for metabolic surgery.

References

Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KGMM, Zimmet PZ, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39(6):861–877. https://doi.org/10.2337/dc16-0236

Moradi M, Kabir A, Khalili D, Pazouki A, Hosseini SR, Golzarand M, et al. Type 2 diabetes remission after Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and one anastomosis gastric bypass (OAGB): results of the longitudinal assessment of bariatric surgery study. BMC Endocr Disord. 2022;22(1):269. https://doi.org/10.1186/s12902-022-01171-8

Schauer PR, Mingrone G, Ikramuddin S, Wolfe B. Clinical outcomes of metabolic surgery: efficacy of glycemic control, weight loss, and remission of diabetes. Diabetes Care. 2016;39(6):902–911. https://doi.org/10.2337/dc16-0520

Dang JT, Sheppard CE, Kim D, de Gara C, Karmali S, Birch DW. Predictive factors for diabetes remission after bariatric surgery. Can J Surg. 2019;62(5):315–319. https://doi.org/10.1503/cjs.014516

Balasubaramaniam V, Pouwels S. Remission of type 2 diabetes mellitus (T2DM) after sleeve gastrectomy (SG), one-anastomosis gastric bypass (OAGB), and Roux-en-Y gastric bypass (RYGB): a systematic review. Medicina (Kaunas). 2023;59(5):985. https://doi.org/10.3390/medicina59050985

Jans A, Näslund I, Ottosson J, Szabo E, Näslund E, Stenberg E. Duration of type 2 diabetes and remission rates after bariatric surgery in Sweden 2007–2015: a registry-based cohort study. PLoS Med. 2019;16(11):e1002985. https://doi.org/10.1371/journal.pmed.1002985

Ghusn W, Zeineddine J, Betancourt RS, Hurtado MD. Advances in metabolic bariatric surgeries and endoscopic therapies: a comprehensive narrative review of diabetes remission outcomes. Medicina (Kaunas). 2025;61(2):350. https://doi.org/10.3390/medicina61020350

Zhou X, Zeng CP, He Q. Diabetes remission of bariatric surgery and nonsurgical treatments in type 2 diabetes patients who failure to meet the criteria for surgery: a systematic review and meta-analysis. BMC Endocr Disord. 2023;23(1):40. https://doi.org/10.1186/s12902-023-01283-9

Golomb I, David MB, Glass A, Kolitz T, Keidar A. Long-term metabolic effects of laparoscopic sleeve gastrectomy. JAMA Surg. 2015;150(11):1051–1057. https://doi.org/10.1001/jamasurg.2015.2202

Purnell JQ, Selzer F, Wahed AS, Pender J, Pories W, Pomp A, et al. Type 2 diabetes remission rates after laparoscopic gastric bypass and gastric banding: results of the longitudinal assessment of bariatric surgery study. Diabetes Care. 2016;39(7):1101–1107. https://doi.org/10.2337/dc15-2138

Simonson DC, Halperin F, Foster K, Vernon A, Goldfine AB. Clinical and patient-centered outcomes in obese patients with type 2 diabetes 3 years after randomization to Roux-en-Y gastric bypass surgery versus intensive lifestyle management: the SLIMM-T2D Study. Diabetes Care. 2018;41(4):670–679. https://doi.org/10.2337/dc17-1OM

Stano S, Alam F, Wu L, Dutia R, Ng S, Sala M, et al. Effect of meal size and texture on gastric pouch emptying and glucagon-like peptide 1 after gastric bypass surgery. Surg Obes Relat Dis. 2017;13(12):1975–1983. https://doi.org/10.1016/j.soard.2017.09.001

Klebanoff MJ, Chhatwal J, Nudel JD, Corey KE, Kaplan LM, Hur C. Cost-effectiveness of bariatric surgery in adolescents with obesity. JAMA Surg. 2017;152(2):136–141. https://doi.org/10.1001/jamasurg.2016.3640

Csendes JA, Papapietro VK, Burgos LA, Lanzarini SE, Csendes PL, Canobra ML. Efecto del bypass gástrico a largo plazo (7 a 10 años) en pacientes con obesidad severa y mórbida sobre el peso corporal, diabetes, dislipidemia y desarrollo de anemia. Rev Med Chile. 2011;139(11):1414–1420. DOI no disponible.

Giraldo Villa A, Serna Zuluaga L, Mustiola C, López G, Donado Gómez J, Toro Montoya A. Factores relacionados con la pérdida de peso en una cohorte de pacientes obesos sometidos a bypass gástrico. Nutr Hosp. 2014;28(3):623–630. https://doi.org/10.3305/nh.2013.28.3.6434

Pereyra F, Oliva J, García B, García J, Suárez B. Eficacia en la remisión de la diabetes mellitus tipo 2 en pacientes sometidos a cirugía bariátrica en nuestro medio. Endocrinol Diabetes Nutr. 2019;66(1):56–61. https://doi.org/10.1016/j.endinu.2018.07.007

Adams TD, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med. 2017;377(12):1143–1155. https://doi.org/10.1056/NEJMoa1700459

Casajoana A, Pujol J, Garcia A, Elvira J, Virgili N, Vilarrasa N, et al. Predictive value of gut peptides in T2D remission: randomized controlled trial comparing metabolic gastric bypass, sleeve gastrectomy and greater curvature plication. Obes Surg. 2017;27(9):2235–2245. https://doi.org/10.1007/s11695-017-2669-7

Gong K, Li K, Zhang N, Zhu B, Du D, Zhang D, et al. Gastric bypass procedure for type 2 diabetes patients with BMI < 28 kg/m². Surg Endosc. 2017;31(3):1172–1179. https://doi.org/10.1007/s00464-016-5085-5

Zhang H, Han X, Du H, Zhang J, Jin P. Effect of Roux-en-Y gastric bypass on remission of T2D: medium-term follow-up in Chinese patients with different BMI obesity class. Obes Surg. 2017;27(1):134–142. https://doi.org/10.1007/s11695-016-2274-1

Vasas P, Dillemans B, Van Cauwenberge S, De Visschere M, Vandendriessche K. Short- and long-term outcomes of laparoscopic Roux-en-Y gastric bypass in patients with type 2 diabetes mellitus. Acta Chir Belg. 2016;116(2):79–87. https://doi.org/10.1080/00015458.2016.1148997

Alnajjar LI, Alzaben MA, Alghamdi AA, Alzahrani RM, Alzahrani HH, Alshahrani FS. The remission rate, metabolic changes, and quality of life assessment among patients with type 2 diabetes post-bariatric surgery in Riyadh, Saudi Arabia. Saudi Med J. 2023;44(7):694–702. https://doi.org/10.15537/smj.2023.44.7.20230080